Want to see ANVS full AI Analyst Report?
ANVS Stock Chart & Stats
$1.78
<$0.01(0.60%)
At close: 4:00 PM EDT
$1.78
<$0.01(0.60%)
Day’s Range― - ―
52-Week Range$1.54 - $5.50
Previous Close$1.67
Volume499.66K
Average Volume (3M)843.51K
Market Cap
$73.28M
Enterprise Value$51.06
Total Cash (Recent Filing)$18.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Nov 11, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding42,606,150
10 Day Avg. Volume708,821
30 Day Avg. Volume843,507
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.67Price Target Upside499.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Phase 3 ExecutionCompleting enrollment in a large, pivotal study reduces execution uncertainty and establishes defined six- and 18-month readouts. This advances buntanetap toward potential regulatory submissions and creates a clearer development pathway.
No Reported DebtThe absence of reported debt limits interest expense, refinancing exposure and lender constraints. This gives Annovis greater flexibility to direct available capital toward clinical development, although it does not eliminate its need for future funding.
Potential Dual-track Regulatory PathwaySeparate submissions tied to symptomatic and disease-modifying outcomes could provide more than one regulatory opportunity for the lead program. If supported by trial data, this approach may broaden buntanetap’s eventual clinical and commercial positioning.
Bears Say
No Commercial RevenueThe absence of product revenue means the company has no demonstrated commercial engine to offset research and development spending. Financial performance therefore remains dependent on clinical progress and continued access to external capital.
Persistent Cash BurnOngoing negative operating and free cash flow indicates that the business is not self-funding its operations. Intensifying burn can shorten the funding runway and increase dependence on additional financing before pivotal development is complete.
Equity Dilution RiskReliance on equity issuance to finance late-stage trials can dilute existing holders and may remain necessary while revenue is absent. Future capital needs could further expand the share base and constrain per-share participation in pipeline success.
Annovis Bio News
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $1.54 and its highest was $5.50 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is $73.28M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Nov 11, 2026 which is in 70 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Aug 14, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.453 by $0.053.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.3.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 42,606,150 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.453. Following the earnings report the stock price went up 3.352%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (499.25% Upside)
$10.67 (499.25% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Annovis Bio
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$10.67
▲(499.25% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
11.30% Insiders
2.59% Mutual Funds
6.63% Other Institutional Investors
75.37% Public Companies and
Individual Investors